Women over 40 are calling for better treatment options after a significant study by Monash University revealed that nearly half of women in midlife experience severe symptoms associated with perimenopause. This study, which surveyed 5,468 Australian women aged 40 to 69, found that 47 percent reported poor sexual wellbeing and symptoms of female sexual dysfunction (FSD).
The findings underscore a critical need for improved healthcare strategies, as symptoms of FSD, including low desire, pain during intercourse, and emotional distress, can lead to depression and relationship strain. Of those surveyed, 2,583 women—just under half—experienced sexually related personal distress. Additionally, one in four women had a diagnosed sexual dysfunction, while another quarter experienced distress without a formal diagnosis.
Significant Gaps in Treatment Options
Senior study author Professor Susan Davis emphasized the urgent need for better treatment and guidance for perimenopausal women. “Given the observed prevalence of FSD in perimenopausal women, best practice guidelines and treatment options for perimenopausal women are much needed,” she stated. Currently, approved medications only address low desire and are limited to premenopausal or postmenopausal women, leaving those in the perimenopausal phase without suitable options.
Professor Davis further highlighted the often-overlooked importance of sexual wellbeing as a crucial component of overall health. “One cannot dismiss the impact that sexual health has, not only on a woman’s intimate relationship, but most importantly on a woman’s general well-being,” she added.
Understanding Perimenopause
Perimenopause is a transitional stage leading up to menopause, during which many women experience changes in sexual wellbeing. This period is marked by fluctuating hormone levels, which can significantly affect both physical and emotional health. Despite its prevalence, perimenopause remains a poorly understood phase, often leaving women without clear clinical guidance or effective treatment options.
The announcement comes as healthcare professionals increasingly recognize the need for comprehensive approaches to women’s health, particularly as it pertains to sexual wellbeing. The lack of tailored treatments for perimenopausal women not only affects individual health outcomes but also has broader implications for public health systems.
Calls for Action and Future Directions
This development follows growing advocacy from women’s health groups and professionals who are urging for more research and better healthcare policies. According to sources, there is a push for the development of new medications and therapies specifically designed for perimenopausal women, as well as updated clinical guidelines that address the unique challenges they face.
“The move represents a significant step towards addressing a long-neglected area of women’s health. By focusing on the specific needs of perimenopausal women, healthcare providers can offer more effective and personalized care,” said an expert in women’s health policy.
Meanwhile, the study’s findings are expected to influence future research and policy decisions, potentially leading to a shift in how perimenopausal health issues are addressed globally. As awareness grows, there is hope that the healthcare industry will respond with innovative solutions that improve the quality of life for millions of women.
Looking forward, experts suggest that increased funding for research and development, alongside educational initiatives for both healthcare providers and patients, will be crucial in bridging the current gaps in treatment. As the conversation around women’s health continues to evolve, the focus on perimenopause could pave the way for more inclusive and effective healthcare solutions.
